Orikine Bio

Orikine Bio is a private, preclinical-stage biotech developing novel cytokine therapeutics using its proprietary Foldikine™ platform. The platform engineers bi-specific cytokines to deliver precise signals to specific cells, aiming to correct immune dysfunction in autoimmune and inflammatory diseases with a high therapeutic index. Founded in 2021/2022, the company has raised €5.5M in seed funding from investors like Asabys and AdBio and has secured significant non-dilutive grant funding. Orikine Bio represents a convergence of computational protein design and immunology, seeking to address a major unmet need in autoimmunity with a potentially safer, more effective modality.

Foldikine™ platform: A proprietary protein-engineering platform designed to create precision-engineered, bi-specific cytokines. It aims to deliver targeted signaling to specific cell types, enhancing therapeutic efficacy, durability, and safety (therapeutic index) for immune system reprogramming.

Orikine competes in the emerging field of cytokine engineering, which includes companies like Synthekine, Sudo Biosciences, and other biotechs developing engineered IL-2, IL-10, or other cytokine variants. It also faces indirect competition from all major immunology-focused biopharma companies (e.g., AbbVie, Johnson & Johnson, Amgen) developing antibodies and small molecules for autoimmune diseases.